There is a possible interaction between oral anticoagulants and pemetrexed; therefore, increase the frequency of International Normalised Ratio monitoring (INR) if treating with oral anticoagulants.
Pregnancy and Lactation
Avoid in pregnancy and do not use in breast-feeding women.
Pemetrexed can be genotoxic; sexually mature males are advised not to father a child during treatment and up to 6 months thereafter. Owing to the possibility of irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment. Women of childbearing potential must use effective contraception during treatment.
It has been reported that pemetrexed can cause somnolence. Patients should be cautioned against driving or operating machinery.
Haematological: Very common: Anaemia, leucopenia, thrombocytopenia, neutropenia. Common: Febrile neutropenia and infection without neutropenia. Uncommon: Pancytopenia.
Gastro-intestinal: Very common: Nausea, vomiting, stomatitis/pharyngitis, anorexia, diarrhoea, constipation. Common: Dyspepsia, abdominal pain. Rare: Colitis.
General: Very common: Fatigue. Common: Fever, conjunctivitis.
Metabolism and nutrition: Common: Dehydration.
Nervous system: Very common: Neuropathy - sensory. Common: Neuropathy - motor, dysgeusia.
Renal and urinary: Very common: Creatinine elevation, creatinine clearance decreased. Common: Renal failure.
Hepatobiliary: Common: SGPT (ALT) elevation and SGOT (AST) elevation, increased GGT. Rare: Cases of hepatitis, potentially serious, have been reported during trials.
Skin and subcutaneous tissue: Very common: Rash/desquamation, alopecia.
Common: Urticaria, allergic reaction/hypersensitivity, erythema m
|SOURCE Eli Lilly and Company|
Copyright©2007 PR Newswire.
All rights reserved